We love biotechs and is TapImmune Inc. (TPIV) Current Reversal due to Catalyst News? Must Read...
As you know we love following biotech companies and their developing stories. We have witnessed some remarkable stories. Where a small unknown biotech company rises from the ashes to become a leader in their field of work. The Cancer or Oncology field possesses these type of characteristics that can drive a small biotech company into the forefront of research. This is the reason why we are very bullish and believe that in coming weeks, thousands of biotech investors will soon discover the potential of this company that we plan on covering for weeks! Our New Biotech & Technical Report is TapImmune Inc. (TPIV)! Put TPIV immediately on your radars as the current technicals have been reversing well past $.20, can this be the start to a new rally? This might very well be the case as they released what most biotech investors look for, catalyst news!
Just over the weekend, TPIV released very promising news that one may consider catalyst, "its Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT's 2nd Annual World Congress on Immunodiseases and Therapy to be held in Guangzhou, China, November 18-20, 2011.
At this meeting, Dr. Wilson will review the role of TAP (Transporters Associated with Antigen Presentation) as a novel target for the development of vaccines for cancer and infectious disease, and the development pathway for TapImmune's technologies. Analysis of clinical samples indicate that a variety of solid tumors (breast, melanoma, ovarian, cervical and lung) have deficiencies in TAP levels, and that TAP levels correlate with lesion size, disease stage, metastatic potential and speed of disease progression. Different TAP genotypes also correlate with cervical cancer risk from oncolytic human papillomaviruses. Collectively, these studies indicate that abnormal expression of TAP genes are part of a widespread mechanism that can result in impaired antigen presentation and immune escape of malignant cells in a variety of tumors. Strategies to restore TAP expression, including clinical programs, will be discussed.
TapImmune's genetic vaccine technology is based on reintroducing TAP (TAP1/TAP2), thereby modulating the activity of the antigen processing machinery to increase effective presentation of antigens or markers to the immune system. The immune system can use this information to selectively destroy cancerous cells or to provoke an immune response against cells infected with pathogens.<Click here to read full news release>.
If you visit their website you can find that TPIV is not your overnight biotech story. It has been around for years.
Cancer, the Immune System, and TAP - In many cancers the tumor associated antigen is missing from MHC class I because the assembly of this complex has been disrupted. This occurs in many tumors because TAP is expressed at very low levels. As a consequence, tumor associated antigens generated in cancerous cells are not transported into the ER, thus preventing the assembly of functional MHC class I antigen. This results in the MHC on the cell surface missing the tumor antigen peptides that identify the cell as being cancerous. These cells, without functional MHC on their cell surface, are hidden from the cellular arm of the immune system and grow into tumors that eventually kill the person. Loss of TAP expression in tumors is highly correlated with disease progression and survival rates in humans. Clinical studies on melanoma when examining primary and metastatic tumors, show a clear and significant correlation between TAP expression and survival. Clinical studies on resected tumors correlate metastasis of breast cancer, prostate cancer, colorectal cancer, small cell lung cancer, renal cancer, squamous cell carcinoma, cervical cancer, laryngeal papillamatosis, with low or absent TAP expression.
You can continue your research to view their various product pipeline and patents here. http://www.tapimmune.com/technology/product_development/
Again put TPIV immediately on your radars as we monitor the current technicals and corporate developments for weeks!
About TapImmune Inc.- http://www.tapimmune.com:
TapImmune's unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing ('TAP'). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP. TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is initiating clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. A next generation smallpox vaccine is currently in preclinical development.
"Finding Value in the Undervalued"
.jpg)
Become a PREMIER VIP MEMBER HERE *INTRODUCTORY PRICE WILL NOT LAST LONG! We work hard to research promising companies in all exchanges. Read our independent research here!
